

ENABLING THE NEXT GENERATION OF NOVEL INSECTICIDES

BIO-GENE TECHNOLOGY LIMITED

30 NOVEMBER 2021

Annual General Meeting

PRESENTED BY

Robert Klupacs


NON-EXECUTIVE CHAIRMAN

Richard Jagger

CEO & MANAGING DIRECTOR



BIO-GENE
TECHNOLOGY
LTD



DISCLAIMER

This presentation has been prepared by Bio-Gene Technology Limited (ASX:BGT) (the Company). This presentation is not, and should not be considered, an offer or invitation to apply for or purchase securities in the Company or as a recommendation or inducement to make an offer or invitation in respect of securities in the Company. No agreement to subscribe for securities will be entered into on the basis of this presentation or any information contained in this presentation.

This presentation is not a prospectus, product disclosure document or other offering document under Australian law or under the law of another jurisdiction. This presentation is provided for general information purposes only and is selective, does not purport to contain all relevant information and has not been independently verified.

Neither the Company nor its advisors have any responsibility or obligation to inform any recipient of any matter arising or coming to their notice after the date of this presentation, which may affect any matter referred to in the presentation. The Company releases material information as announcements to the ASX (ASX:BGT). Recipients seeking further information in respect of the Company should review the Company's announcements as released to ASX from time to time.

Nothing in this presentation constitutes investment, legal, tax, accounting or other advice. The recipient should consider its own financial situation, objectives and needs and conduct its own independent investigation and assessment, including obtaining investment, legal, tax, accounting or other advice as it considers necessary or appropriate.

The distribution of this presentation (including electronic copies) outside Australia may be restricted by law and persons who come into possession of this presentation outside Australia should seek advice on and observe any such restrictions. Any failure to comply with such restrictions may constitute a violation of applicable securities laws.

This presentation may contain statements relating to intentions, future acts and events (Forward Looking Statements). Forward Looking Statements involve subjective judgment and analysis, known and unknown risks, uncertainties and other important factors that cause those future acts, events and circumstances to differ from the way or manner in which they are expressly or impliedly portrayed. No representation, warranty or guarantee, express or implied, is given that any Forward Looking Statements will be achieved or proven correct, or that any assumptions or projections on which the Forward Looking Statements are based are reasonable.

No financial information (unless also contained in financial reports released to ASX), estimates or projections contained in this presentation or as derived from such financial information, estimates or projections can be relied upon as a promise or representation as to any present or future matter.

To the maximum extent permitted by law, neither the Company nor any of its associates, directors, officers, employees, advisors or representatives make any representation or provide any warranty, express or implied, as to the accuracy, reliability or completeness of the information contained in this presentation or any subsequent information provided to the recipient including, but not limited to, any financial projections, estimates or other historical information.

OUR STRATEGIC OBJECTIVE

Generate multiple revenue streams from technology licensing fees, milestone payments and royalties by



Securing & owning active ingredient product registrations



Working with strong commercial partners on product development; marketing and distribution




Developing proprietary manufacturing and production know-how



Potential partnership agreements across multiple geographies and different end-use markets, with collaboration programs now underway in two of our target segments

IMPORTANT POSITIVE PROGRESS OVER THE PAST 12 MONTHS



2021 FINANCIAL YEAR



CONSUMER PRODUCTS: EVERGREEN COMMERCIAL DEVELOPMENT AGREEMENT

Evergreen is a market leader in consumer products across Europe and in Australia/New Zealand

Initial Field of Use

Fly & mosquito electric evaporator
Ant bait gel and ant spray

ROFR to negotiate additional applications within consumer market

Initial Territory

E.U., U.K., A/NZ
ROFR to negotiate additional territories within consumer market

Revenue Model

Up-front licence fee
Milestone payments prior to registration
On-going royalties on end-use product sales
Development costs borne by Evergreen

Market Opportunity

Initial Field of Use:
US\$600m¹

Total European consumer insecticide market: US\$2b¹



PUBLIC HEALTH: NEW OPTION AGREEMENT SIGNED ON CLARKE MOSQUITO PROJECT

Clarke is the largest vertically integrated company in public health mosquito control

Results of Phase 2 Testing

Very positive results indicate the suitability of Bio-Gene products as mosquito control technology

Target formulations identified for progression to Phase 3 field trials

Confidence for both companies to move forward with commercial negotiations as per the Option agreement

New Option Agreement Signed

90 Days to complete full commercial terms

Exclusive period to begin Phase 3 field testing

Agreement is for the U.S. market

Cost of studies borne by Clarke, with shared report of results

Next Steps

Clarke to confirm timing for the field component of Phase 3 trials (somewhat weather dependent)

Field studies designed to confirm suitability of laboratory developed formulations for field use & EPA registration

Market Opportunity

Initial Field of Use:
US\$100m¹

Global market \$650m¹



¹ Global Mosquito Control Market, Research Report 2020, Forecast to 2026

CROP PROTECTION: UPDATE ON BASF STORED GRAIN PROJECT

BASF is the world's largest chemical company

Details of Current Agreement with BASF

Term of exclusivity to have option for stored grain market within Australia

Results of Phase 3 Testing

Field testing will be completed Nov/Dec 2021

Lab testing required to test stored grain efficacy F1 progeny

Report to then be generated

Final reporting on these results expected early in 2022

Further Discussions

Bio-Gene and BASF are discussing terms covering the commitment required of each party to progress the commercial development of Flavocide as a stored grain protectant

Final stage of Phase 3 will show the ability for Flavocide, when used in combination, to control the full range of stored grain pests, over 9 months (commercially acceptable time frame).

Market opportunity in Australia is relatively small, but there is significant global potential (A\$1b)¹



IMPORTANT PROGRESS ACROSS OTHER KEY AREAS

I.P. Developments

- Additional research underway has the potential to identify new I.P. for the company
- I.P. can be in the form of patents, technical knowhow, trade secrets

Review Of Reg Requirements

- Completed a regulatory review analysis with global consultants to look at the specific data requirements for USA, European Union and Australia across our different market segments
- Clear understanding developed relating to read-across potential for different applications and regulatory jurisdictions.

Additional MTAs

- Bio-Gene has signed 4 new MTAs this calendar year with international companies focused across all areas of insecticide use
- Studies performed by these companies ultimately give Bio-Gene additional options for going to market

Manufacturing

- Flavocide manufacturing validation – scale-up process has confirmed ability to produce larger quantities
- Qcide: Last harvest confirmed production improvements based on modified temperature and pressure

Efficacy testing

- Additional studies underway for specific company evaluation of technology
 - Animal Health
 - Consumer
 - Crop Protection
 - Public Health
- Extension work to identify additional key targets and applications to support our commercial discussions and further develop our I.P. portfolio

Patent Allowances

- 2 granted in Australia
- 1 recently granted in United States
- Under review in other key markets

On-going research is focused on developing data to support key commercial discussions as well as enhancing our I.P. portfolio
Bio-Gene continues to expand its market network and identify new data that further differentiates our I.P. position

KEY PRIORITIES FOR THE NEXT 12 MONTHS

Progressing development work associated with existing partnerships


Advancing the terms of our partnerships

Broadening our future opportunities via MTA relationships


Building our data to support efficacy, novel Mode of Action and regulatory approvals

Optimising our manufacturing and production processes

Strengthening our IP



A CLEAR ROAD MAP FOR GENERATING VALUE – MEDIUM TERM



ENABLING THE NEXT GENERATION OF NOVEL INSECTICIDES

BIO-GENE TECHNOLOGY LIMITED

30 NOVEMBER 2021

Annual General Meeting

THANK YOU

BIO-GENE
TECHNOLOGY
LTD

